These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 28222702)

  • 1. The virological durability of first-line ART among HIV-positive adult patients in resource limited settings without virological monitoring: a retrospective analysis of DART trial data.
    Dolling DI; Goodall RL; Chirara M; Hakim J; Nkurunziza P; Munderi P; Eram D; Tumukunde D; Spyer MJ; Gilks CF; Kaleebu P; Dunn DT; Pillay D;
    BMC Infect Dis; 2017 Feb; 17(1):160. PubMed ID: 28222702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High level of viral suppression and low switch rate to second-line antiretroviral therapy among HIV-infected adult patients followed over five years: retrospective analysis of the DART trial.
    Kityo C; Gibb DM; Gilks CF; Goodall RL; Mambule I; Kaleebu P; Pillay D; Kasirye R; Mugyenyi P; Walker AS; Dunn DT;
    PLoS One; 2014; 9(3):e90772. PubMed ID: 24625508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Virological response and resistance among HIV-infected children receiving long-term antiretroviral therapy without virological monitoring in Uganda and Zimbabwe: Observational analyses within the randomised ARROW trial.
    Szubert AJ; Prendergast AJ; Spyer MJ; Musiime V; Musoke P; Bwakura-Dangarembizi M; Nahirya-Ntege P; Thomason MJ; Ndashimye E; Nkanya I; Senfuma O; Mudenge B; Klein N; Gibb DM; Walker AS;
    PLoS Med; 2017 Nov; 14(11):e1002432. PubMed ID: 29136032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts.
    Munderi P; Walker AS; Kityo C; Babiker AG; Ssali F; Reid A; Darbyshire JH; Grosskurth H; Mugyenyi P; Gibb DM; Gilks CF;
    HIV Med; 2010 May; 11(5):334-44. PubMed ID: 20136661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
    Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
    Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues.
    Santoro MM; Sabin C; Forbici F; Bansi L; Dunn D; Fearnhill E; Boumis E; Nicastri E; Antinori A; Palamara G; Callegaro A; Francisci D; Zoncada A; Maggiolo F; Zazzi M; Perno CF; Ceccherini-Silberstein F; Mussini C
    HIV Med; 2013 Oct; 14(9):571-7. PubMed ID: 23668660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): a 5-year open-label randomised factorial trial.
    ARROW Trial team
    Lancet; 2013 Apr; 381(9875):1391-1403. PubMed ID: 23473847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction with lopinavir-based treatment followed by switch to nevirapine-based regimen versus non-nucleoside reverse transcriptase inhibitors-based treatment for first line antiretroviral therapy in HIV infected children three years and older.
    Alvarez-Uria G; Pakam R; Naik PK; Midde M
    PLoS One; 2014; 9(9):e108063. PubMed ID: 25232730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis.
    Boyd MA; Moore CL; Molina JM; Wood R; Madero JS; Wolff M; Ruxrungtham K; Losso M; Renjifo B; Teppler H; Kelleher AD; Amin J; Emery S; Cooper DA;
    Lancet HIV; 2015 Feb; 2(2):e42-51. PubMed ID: 26424460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial.
    ; Mugyenyi P; Walker AS; Hakim J; Munderi P; Gibb DM; Kityo C; Reid A; Grosskurth H; Darbyshire JH; Ssali F; Bray D; Katabira E; Babiker AG; Gilks CF; Grosskurth H; Munderi P; Kabuye G; Nsibambi D; Kasirye R; Zalwango E; Nakazibwe M; Kikaire B; Nassuna G; Massa R; Fadhiru K; Namyalo M; Zalwango A; Generous L; Khauka P; Rutikarayo N; Nakahima W; Mugisha A; Todd J; Levin J; Muyingo S; Ruberantwari A; Kaleebu P; Yirrell D; Ndembi N; Lyagoba F; Hughes P; Aber M; Lara AM; Foster S; Amurwon J; Wakholi BN; Whitworth J; Wangati K; Amuron B; Kajungu D; Nakiyingi J; Omony W; Fadhiru K; Nsibambi D; Khauka P; Mugyenyi P; Kityo C; Ssali F; Tumukunde D; Otim T; Kabanda J; Musana H; Akao J; Kyomugisha H; Byamukama A; Sabiiti J; Komugyena J; Wavamunno P; Mukiibi S; Drasiku A; Byaruhanga R; Labeja O; Katundu P; Tugume S; Awio P; Namazzi A; Bakeinyaga GT; Katabira H; Abaine D; Tukamushaba J; Anywar W; Ojiambo W; Angweng E; Murungi S; Haguma W; Atwiine S; Kigozi J; Namale L; Mukose A; Mulindwa G; Atwiine D; Muhwezi A; Nimwesiga E; Barungi G; Takubwa J; Murungi S; Mwebesa D; Kagina G; Mulindwa M; Ahimbisibwe F; Mwesigwa P; Akuma S; Zawedde C; Nyiraguhirwa D; Tumusiime C; Bagaya L; Namara W; Kigozi J; Karungi J; Kankunda R; Enzama R; Latif A; Hakim J; Robertson V; Reid A; Chidziva E; Bulaya-Tembo R; Musoro G; Taziwa F; Chimbetete C; Chakonza L; Mawora A; Muvirimi C; Tinago G; Svovanapasis P; Simango M; Chirema O; Machingura J; Mutsai S; Phiri M; Bafana T; Chirara M; Muchabaiwa L; Muzambi M; Mutowo J; Chivhunga T; Chigwedere E; Pascoe M; Warambwa C; Zengeza E; Mapinge F; Makota S; Jamu A; Ngorima N; Chirairo H; Chitsungo S; Chimanzi J; Maweni C; Warara R; Matongo M; Mudzingwa S; Jangano M; Moyo K; Vere L; Mdege N; Machingura I; Katabira E; Ronald A; Kambungu A; Lutwama F; Mambule I; Nanfuka A; Walusimbi J; Nabankema E; Nalumenya R; Namuli T; Kulume R; Namata I; Nyachwo L; Florence A; Kusiima A; Lubwama E; Nairuba R; Oketta F; Buluma E; Waita R; Ojiambo H; Sadik F; Wanyama J; Nabongo P; Oyugi J; Sematala F; Muganzi A; Twijukye C; Byakwaga H; Ochai R; Muhweezi D; Coutinho A; Etukoit B; Gilks C; Boocock K; Puddephatt C; Grundy C; Bohannon J; Winogron D; Gibb DM; Burke A; Bray D; Babiker A; Walker AS; Wilkes H; Rauchenberger M; Sheehan S; Spencer-Drake C; Taylor K; Spyer M; Ferrier A; Naidoo B; Dunn D; Goodall R; Darbyshire JH; Peto L; Nanfuka R; Mufuka-Kapuya C; Kaleebu P; Pillay D; Robertson V; Yirrell D; Tugume S; Chirara M; Katundu P; Ndembi N; Lyagoba F; Dunn D; Goodall R; McCormick A; Lara AM; Foster S; Amurwon J; Wakholi BN; Kigozi J; Muchabaiwa L; Muzambi M; Weller I; Babiker A; Bahendeka S; Bassett M; Wapakhabulo AC; Darbyshire JH; Gazzard B; Gilks C; Grosskurth H; Hakim J; Latif A; Mapuchere C; Mugurungi O; Mugyenyi P; Burke C; Jones S; Newland C; Pearce G; Rahim S; Rooney J; Smith M; Snowden W; Steens JM; Breckenridge A; McLaren A; Hill C; Matenga J; Pozniak A; Serwadda D; Peto T; Palfreeman A; Borok M; Katabira E
    Lancet; 2010 Jan; 375(9709):123-31. PubMed ID: 20004464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early virological suppression with three-class antiretroviral therapy in HIV-infected African infants.
    Prendergast A; Mphatswe W; Tudor-Williams G; Rakgotho M; Pillay V; Thobakgale C; McCarthy N; Morris L; Walker BD; Goulder P
    AIDS; 2008 Jul; 22(11):1333-43. PubMed ID: 18580613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa.
    DART Virology Group and Trial Team
    AIDS; 2006 Jun; 20(10):1391-9. PubMed ID: 16791013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial.
    Gibb DM; Kizito H; Russell EC; Chidziva E; Zalwango E; Nalumenya R; Spyer M; Tumukunde D; Nathoo K; Munderi P; Kyomugisha H; Hakim J; Grosskurth H; Gilks CF; Walker AS; Musoke P;
    PLoS Med; 2012; 9(5):e1001217. PubMed ID: 22615543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Virological failure reduced with HIV-serostatus disclosure, extra baseline weight and rising CD4 cells among HIV-positive adults in Northwestern Uganda.
    Izudi J; Alioni S; Kerukadho E; Ndungutse D
    BMC Infect Dis; 2016 Oct; 16(1):614. PubMed ID: 27793124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial.
    ; Babiker A; Castro nee Green H; Compagnucci A; Fiscus S; Giaquinto C; Gibb DM; Harper L; Harrison L; Hughes M; McKinney R; Melvin A; Mofenson L; Saidi Y; Smith ME; Tudor-Williams G; Walker AS
    Lancet Infect Dis; 2011 Apr; 11(4):273-83. PubMed ID: 21288774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of triple-class virological failure in children with HIV: a retrospective cohort study.
    ; Castro H; Judd A; Gibb DM; Butler K; Lodwick RK; van Sighem A; Ramos JT; Warsawski J; Thorne C; Noguera-Julian A; Obel N; Costagliola D; Tookey PA; Colin C; Kjaer J; Grarup J; Chene G; Phillips A
    Lancet; 2011 May; 377(9777):1580-7. PubMed ID: 21511330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accumulation of HIV-1 drug resistance in patients on a standard thymidine analogue-based first line antiretroviral therapy after virological failure: implications for the activity of next-line regimens from a longitudinal study in Mozambique.
    De Luca A; Sidumo ZJ; Zanelli G; Magid NA; Luhanga R; Brambilla D; Liotta G; Mancinelli S; Marazzi MC; Palombi L; Ceffa S
    BMC Infect Dis; 2017 Sep; 17(1):605. PubMed ID: 28870148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Very high baseline HIV viremia impairs efficacy of non-nucleoside reverse transcriptase inhibitor-based ART: a long-term observation in treatment-naïve patients.
    Chen S; Han Y; Song XJ; Li YL; Zhu T; Lu HZ; Tang XP; Zhang T; Zhao M; He Y; He SH; Wang M; Li YZ; Huang SB; Li Y; Liu J; Cao W; Li TS
    Infect Dis Poverty; 2020 Jun; 9(1):75. PubMed ID: 32571409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of antiretroviral therapy in HIV-infected children under 2 years of age.
    Penazzato M; Prendergast A; Tierney J; Cotton M; Gibb D
    Cochrane Database Syst Rev; 2012 Jul; (7):CD004772. PubMed ID: 22786492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-line antiretroviral therapy durability in a 10-year cohort of naïve adults started on treatment in Uganda.
    Castelnuovo B; Kiragga A; Mubiru F; Kambugu A; Kamya M; Reynolds SJ
    J Int AIDS Soc; 2016; 19(1):20773. PubMed ID: 27319742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.